Imagene AI

Imagene AI shines in its ability to extract biomarker information from routine H&E slides, reducing reliance on expensive and time-consuming IHC or genomic tests. Its deep learning models show strong accuracy for common biomarkers (EGFR, PD-L1, HER2) and molecular subtyping. The explainable heatmaps help pathologists trust predictions. However, the platform requires digitized whole-slide images, which many labs lack. Contact-only pricing suggests high costs, limiting accessibility for smaller institutions. Regulatory coverage is region-specific (CE-IVD in Europe, FDA status unclear). Performance on rare biomarkers may be weaker. Integration with LIS/PACS is smooth, but no public API documentation is available. Overall, Imagene is a powerful research and clinical triage tool for well-equipped labs and pharma partners.

Imagene AI is a clinical-grade AI platform that performs biomarker profiling directly from digitized hematoxylin and eosin (H&E) biopsy images, eliminating the need for immunohistochemistry (IHC) or next-generation sequencing. Designed for pathologists, oncologists, and pharmaceutical researchers, it delivers rapid molecular insights—such as EGFR, PD-L1, HER2, and Ki-67 status—within minutes instead of days. Its deep learning models, trained on millions of annotated slides, also classify molecular subtypes and infer mutation status (e.g., EGFR, KRAS, BRAF). Explainability features highlight morphological patterns behind each prediction. The platform is CE-IVD certified, cloud-based, HIPAA/GDPR compliant, and integrates with LIS/PACS. Custom model training is available for research cohorts. Pricing is contact-only, suggesting enterprise-level costs.